Researchers reported that oncogenic KRAS reprograms adenosine metabolism by upregulating NT5E and suppressing ADA, creating an immunosuppressive tumor microenvironment. In preclinical models, targeting this axis—through ADA nanoparticles, NT5E silencing, or A2AR blockade—reversed immune resistance and improved sensitivity to immunotherapy. The work connects metabolic rewiring to functional immune suppression and points to actionable combination strategies for KRAS-driven cancers. It also emphasizes the role of extracellular adenosine signaling as a gatekeeper of T-cell activity in the tumor microenvironment. If validated in clinical settings, the approach could guide biomarker development around adenosine pathway activity and inform combination regimens with checkpoint inhibitors.